Application DetailsWestern Blotting (WB), Immunocytochemistry (ICC) and Immunohistochemistry (IHC). WB: A dilution of 1:5,000 is recommended. ICC: A dilution of 1:1,000-1:5,000 using fluorescent secondary antibodies or peroxidase or other enzyme-linked methods is recommended on 4% PFA fixed cells in culture, with 3hr-o/n incubation of primary antibody. IHC: 4% PFA frozen tissues, permeabilized. IHC (paraffin-embedded): capable, HEIR treatment typically necessary. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
TargetGlial fibrillary acidic protein (GFAP)
SpecificityThe specificity of this antibody has been confirmed by WB. Human, Rat, Mouse, Feline. Predicted to react with other mammals.
Target Host SpeciesHuman
Species ReactivityCat, Human, Mouse, Other Mammals (Predicted), Rat
Antibody HostChicken
Antibody TypePolyclonal
Antibody IsotypeIgY
ConjugateUnconjugated
Immunogen DescriptionRecombinant GFAP (expressed in E.coli) and native bovine GFAP
Purity DescriptionIgY
FormatLyophilized, without preservatives.
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute with 50 µL sterile-filtered, ultrapure water. Centrifuge to remove any insoluble material.
Storage InstructionsAfter reconstitution of lyophilized antibody, aliquot and store at -20°C for a higher stability. Avoid freeze-thaw cycles.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesAstrocyte; Glial fibrillary acidic protein; GFAP;
Scientific BackgroundGlial fibrillary acidic protein (GFAP) is approx. 50 kDa intra-cytoplasmic filamentous protein of the cytoskeleton in astrocytes. During the development of the central nervous system, it is a cell-specific marker that distinguishes astrocytes from other glial cells. GFAP immunoreactivity has been shown in immature oligodendrocytes, epiglottic cartilage, pituicytes, papillary meningiomas, myoepithelial cells of the breast and in non-CNS: Schwann cells, salivary gland neoplasms, enteric glia cells, and metastasizing renal carcinomas.
Mixed cultures of neurons and glia stained with Chicken polyclonal antibody to Glial Fibrillary Acidic Protein C-1373-50 (red) and DNA (blue). Astrocytes stain strongly and specifically in a clearly filamentous fashion with this antibody.
Left: Analysis of GFAP expression (green) in mouse hippocampus section by Immunohistochemistry. Section was stained with chicken anti-GFAP antibody (1:5,000) and co-stained with rabbit antibody to FOX3/NeuN (R-3770-100, 1:5,000, red). Blue: DAPI nuclear stain. IHC Method: Following transcardial perfusion with 4% PFA, mouse brain was post fixed for 24 hours, cut into 45 uM sections, and free-floating sections were stained. The GFAP antibody stains a network of astroglial cells, while the Fox3/NeuN antibody stains the nuclei and proximal perikarya of neurons. Right: Western blot analysis of GFAP expression in whole rat (2) and mouse (3) brain lysates using chicken anti-GFAP antibody (1:5,000). The strong band at about 50 kDa corresponds to GFAP protein. Smaller proteolytic fragments and alternate transcripts of GFAP may also be detected on such blots.
Specific ReferencesHascup KN et al. (2020) Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice. J Neurochem. [Epub ahead of print]Application: Mouse, IHC(IF).
General ReferencesBrenner M. et al (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001 Jan;27(1):117-20.
1800 605-5127
+61 (0)8 8352 7711
